Identity
Other names: ST3 (stromelysin-3); MMP-11 (matrix metalloproteinase 11) HGNC (Hugo): MMP11 Location: 22q11.2
DNA/RNA
Description 8 exons and 7 introns spanning 11.5 kb; cDNA: 2247 bp, coding sequence 1464 bp.
Transcription
Expression is induced by retinoic acid and TPA through a DR1-type responsive element and a C/EBP binding site, respectively, expression is induced by epithelial cells in a paracrin manner.
Protein
Description 488 amino-acids; 51 kDa; functional domains: signal peptide, targeting the protein to the secretory pathway, prodomain containing a furin-type cleavage site responsible for the intracellular activation, catalytic domain containing a zinc binding site, hemopexin-like domain.
Expression
Cells of mesenchymal origin, notably fibroblastic cells, macrophages, osteoclasts.
Function
Extracellular zinc-dependent proteinase expressed during tissu remodelling processes (development, wound healing) and whose specific substrate is unknown.
Homology
Member of the matrix metalloproteinases (MMP) subfamily of matrixins.
Implicated in various cancer:
Disease Expression of ST3 in 80 to 100% invasive carcinomas of the breast, colon, head and neck, lung, ovary, pancreas, prostate, skin (basal cell carcinoma), uterus (cervix carcinoma and endometrial carcinoma) and in some non-invasive carcinomas that have a high risk of evolving towards invasion; also expression in: fibroblastic stromal cells in the close vicinity of cancerous epithelial cells. Prognosis Prognostic factor of invasion and aggressiveness of the tumors.
